stockrowErnexa Therapeutics Inc.
ERNA Healthcare Biotechnology
Ernexa Therapeutics Inc.’s revenue for fiscal 2024 (year ended December 2024) was $582,000.00, up 755.9% from fiscal 2023.
- Revenue
- −94.1%
- EPS
- +77.7%
- Free cash flow
- −64.1%
Quarter to June 2026, against a year earlier
Follow ERNA
Alert me
Ernexa Therapeutics Inc. (ERNA) EV/Sales
As of 6 November 2026, Ernexa Therapeutics Inc. (ERNA) trades at a EV/Sales of 50.8×. Over the past ten years it has ranged from −0.9× (November 2022) to 1,168,652× (May 2015); the current reading is higher than 75% of that period. That is above the Biotechnology industry median of 9.0× and above the Healthcare sector median of 3.6×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2024 | 59.5× | 1,600.37% |
| FY2023 | 3.5× | (73.28%) |
| FY2020 | 13.1× | 4,090.91% |
| FY2020 | 0.3× | 1.46% |
| FY2019 | 0.3× | 1.75% |
| FY2019 | 0.3× | 0.43% |
| FY2018 | 0.3× | (55.45%) |
| FY2018 | 0.7× | 0.00% |
| FY2017 | 0.7× | (6.71%) |
| FY2017 | 0.7× | 0.00% |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Dec 2024 | 59.5× | 5.42% |
| Sep 2024 | 56.4× | (45.56%) |
| Jun 2024 | 104× | 755.92% |
| Mar 2024 | 12.1× | 246.18% |
| 26 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| AFMDQ Affimed N.V. compare | −19.2× |
| JUNS Jupiter Neurosciences, Inc. compare | n/m |
| CMND Clearmind Medicine Inc. compare | n/m |
| MBIO Mustang Bio, Inc. compare | n/m |
| BCAB BioAtla, Inc. compare | 0.7× |
| SXTP 60 Degrees Pharmaceuticals Inc. compare | 1.5× |
| KALA KALA BIO, Inc. compare | 8.0× |
| ADXN Addex Therapeutics Ltd. Sponsored ADR compare | 8.7× |
| ERNA Ernexa Therapeutics Inc. | 50.8× |
| Biotechnology industry median | 9.0× |
| Healthcare sector median | 3.6× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)